Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies [Yahoo! Finance]